UCB announces EMA bimekizumab verdict
In two studies the therapy demonstrated improvements when compared with the placebo
Read More
Tag: bimekizumab
Positive CHMP opinion for UCB’s bimekizumab
Therapy concerns the treatment of adults with axial spondyloarthritis and psoriatic arthritis
Read More
Interim trial data for UCB’s bimekizumab shows positive results
High levels of skin clearance achieved for moderate to severe plaque psoriasis patients
Read More
UCB’s bimekizumab data in plaque psoriasis published in The Lancet
Phase III BE VIVID and BE READY studies both met their co-primary endpoints
Read More
FDA and EMA accept regulatory submissions for UCB’s bimekizumab
UCB is seeking approval for treatment in moderate-to-severe plaque psoriasis
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
